Background

Vaginal symptoms are a leading cause of primary care visits for women. Individuals exhibiting symptoms often receive laboratory testing based on clinic-specific standards of care. Thus, women seen at a family practice clinic might only receive a vaginitis workup, whereas those seen at a sexually transmitted diseases clinic could be more likely to receive only sexually transmitted infection (STI) testing.

Methods

The likelihood of STIs was assessed in women from whom samples were tested for vaginitis using a molecular diagnostic assay. Positivity rates for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis DNA, detected using the BD MAX CT/GC/TV assay, were calculated. Concordance between the BD MAX Vaginal Panel and the BD MAX CT/GC/TV assay for detection of T. vaginalis was determined.

Results

Women with bacterial vaginosis alone or with concurrent Candida spp infections had high rates of coinfection with sexually transmitted infections (24.4%–25.7%); samples from women who were negative for vaginitis had significantly lower positivity rates (7.9%; P < .001). Trichomonas vaginalis results were concordant between the BD MAX Vaginal Panel and the BD MAX CT/GC/TV assay in 559 of 560 samples tested.

Conclusions

These data suggest, as have other studies, that women with vaginitis symptoms may be at risk for an STI. Molecular testing could provide broad diagnostic coverage for symptomatic women and improve patient management, regardless of the type of clinic in which patients are treated.

中文翻译：

---

使用先前收集的用于阴道炎诊断的样本进行的基于分子的性传播感染检测

背景

阴道症状是女性进行初级保健就诊的主要原因。表现出症状的个体通常会根据临床特定的护理标准接受实验室测试。因此，在家庭诊所就诊的妇女可能只接受阴道炎检查，而在性传播疾病诊所就诊的妇女更有可能仅接受性传播感染（STI）测试。

方法

使用分子诊断测定法评估了样本中患有阴道炎的女性的性传播感染可能性。计算了使用BD MAX CT / GC / TV分析检测到的沙眼衣原体，淋病奈瑟氏球菌和阴道滴虫DNA的阳性率。确定了BD MAX阴道壁板和BD MAX CT / GC / TV检测方法之间的一致性，以检测阴道毛滴虫。

结果

单独患有细菌性阴道病或同时患有假丝酵母菌感染的妇女合并性传播感染的比例很高（24.4％–25.7％）；阴道炎阴性的女性样本的阳性率明显较低（7.9％； P <.001）。在560个样本中的559个样本中，阴道毛滴虫的结果与BD MAX阴道板和BD MAX CT / GC / TV分析结果一致。

结论

这些数据表明，与其他研究一样，患有阴道炎症状的女性可能有性传播感染的风险。分子测试可以为有症状的女性提供广泛的诊断范围，并改善患者管理，而与治疗患者的诊所类型无关。